- Conditions
- Cancer Patients First-ever Acute Ischemic Stroke
- Interventions
- Enoxaparin, Aspirin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 155
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
- Drug · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,050 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 567
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • New Haven, Connecticut • Newark, Delaware + 32 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension
- Interventions
- Droxidopa capsules, Placebo capsules
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 168
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 226
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 179 more
- Conditions
- Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasms, Pancreatic Diseases, Digestive System Diseases, Endocrine System Diseases, Gemcitabine, Antimetabolites, Antineoplastic
- Interventions
- nab-Paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 866 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 107
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 51 more
- Conditions
- Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma, Recurrent HER2-Positive Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma
- Interventions
- Atezolizumab, Biopsy, Bone Scan, Computed Tomography, Docetaxel, Magnetic Resonance Imaging, Paclitaxel, Pertuzumab, Placebo Administration, Quality-of-Life Assessment, Trastuzumab
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 662
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 506 more
- Conditions
- Parkinson Disease, Early Parkinson's Disease
- Interventions
- P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg, Marketed Pramipexole ER
- Drug
- Lead sponsor
- Pharma Two B Ltd.
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 45
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more
- Conditions
- Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 338
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more
- Conditions
- Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
- Interventions
- Proton Therapy, Photon Therapy
- Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2031
- U.S. locations
- 27
- States / cities
- Atlanta, Georgia • Warrenville, Illinois • Baltimore, Maryland + 18 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
- Procedure · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 262
- States / cities
- Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more
- Conditions
- Primary Mediastinal Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 215
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more
- Conditions
- Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
- Interventions
- Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5,018 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1435
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Interventions
- Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography, Hormone Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
- Drug · Procedure · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2034
- U.S. locations
- 348
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 259 more
- Conditions
- Polycythemia Vera
- Interventions
- Rusfertide, Placebo
- Drug
- Lead sponsor
- Protagonist Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 293 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 80
- States / cities
- Mobile, Alabama • Glendale, Arizona • Duarte, California + 66 more
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Selumetinib Sulfate
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 292
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 229 more
- Conditions
- Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer
- Interventions
- Immunotherapy CARE Program
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Prostate Cancer
- Interventions
- Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
- Drug · Radiation
- Lead sponsor
- University of Sydney
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 19
- States / cities
- Boston, Massachusetts • Brighton, Massachusetts • Burlington, Massachusetts + 15 more
- Conditions
- Bladder Cancer, Urothelial Carcinoma
- Interventions
- OGX-427, Docetaxel
- Drug
- Lead sponsor
- Noah Hahn, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Duarte, California • Lancaster, California + 27 more
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma
- Interventions
- Atezolizumab, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 9
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma
- Interventions
- Clinical Observation, Docetaxel, Doxorubicin Hydrochloride, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim
- Other · Drug · Biological
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 608
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 374 more
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
- Interventions
- Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 2,175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2038
- U.S. locations
- 999
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more
- Conditions
- Hepatectomy
- Interventions
- Methylprednisolone
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 19
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 14 more
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Carboplatin, Computed Tomography, Paclitaxel, Pembrolizumab, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 813 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 370
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 272 more